cancer

Tessa Therapeutics Forges $120 Million Joint Venture to Develop Cell Therapies in China
Tessa Therapeutics Forges $120 Million Joint Venture to Develop Cell Therapies in China
BioSpace
Tessa Therapeutics
cell therapy
cancer
China-Singapore Guangzhou Knowledge City
China
Flag link:
Biotechs dive deeper into targeted cancer research, despite costs
Biotechs dive deeper into targeted cancer research, despite costs
Biopharma Dive
biotech
clinical trials
cancer
drug development
Flag link:
ASCO 2019: The Long Game, Targeted Pills, First-Ever Buzz & More
ASCO 2019: The Long Game, Targeted Pills, First-Ever Buzz & More
Xconomy
ASCO 2019
cancer
immunotherapy
diagnostics
Veracyte
Grail
Moderna Therapeutics
Amgen
Nektar Therapeutics
Blueprint Medicines
Merck
AstraZeneca
Roche
breast cancer
Flag link:
The Affordable Care Act erased a racial disparity in cancer care, a new study says
The Affordable Care Act erased a racial disparity in cancer care, a new study says
Stat
cancer
Medicaid
Affordable Care Act
racial discrimination
Flag link:
ASCO 2019 preview: Big Pharmas looking for cancer R&D revival as we hit next-gen crossroads
ASCO 2019 preview: Big Pharmas looking for cancer R&D revival as we hit next-gen crossroads
Fierce Biotech
ASCO 2019
R&D
cancer
oncology
Flag link:
Grail, a deep-pocketed startup, outlines its plans for a blood test to detect cancer
Grail, a deep-pocketed startup, outlines its plans for a blood test to detect cancer
Stat
Grail
diagnostics
ASCO 2019
cancer
Flag link:
Bayer to work with Foundation Medicine on selecting cancer patients
Bayer to work with Foundation Medicine on selecting cancer patients
Reuters
Bayer
Foundation Medicine
Roche
cancer
Vitrakvi
genetic sequencing
Flag link:
FDA should reassess postmarket trials for cancer drugs approved via accelerated pathway, researchers say
FDA should reassess postmarket trials for cancer drugs approved via accelerated pathway, researchers say
Endpoints
FDA
cancer
postmarketing studies
accelerated approvals
Flag link:
A lifesaver with a catch: Powerful new cancer drugs can trigger diabetes — and no one is certain why
A lifesaver with a catch: Powerful new cancer drugs can trigger diabetes — and no one is certain why
Stat
type 1 diabetes
checkpoint inhibitors
cancer
Flag link:
AstraZeneca pivots to early-stage cancer in search of a niche
AstraZeneca pivots to early-stage cancer in search of a niche
Fierce Pharma
AstraZeneca
cancer
Jose Baselga
Flag link:
Ideaya wraps $50M IPO to fuel clinical drive on synthetic lethality
Ideaya wraps $50M IPO to fuel clinical drive on synthetic lethality
Endpoints
Ideaya
IPOs
cancer
Flag link:
Dynavax cuts staff in retreat from cancer research
Dynavax cuts staff in retreat from cancer research
Biopharma Dive
Dynavax Technologies
layoffs
restructuring
cancer
R&D
Flag link:
Affimed scraps T-cell engager program, parts company with CSO
Affimed scraps T-cell engager program, parts company with CSO
Fierce Biotech
Affimed
bispecific antibodies
T-cell engager
cancer
Flag link:
Can AI Tools Segment A Cancer Tumor As Well As An Oncologist?
Can AI Tools Segment A Cancer Tumor As Well As An Oncologist?
Forbes
Harvard
artificial intelligence
cancer
diagnostics
cancer radiation therapy
Flag link:
Commentary: Novartis CEO: Gene therapy offers hope of cures in one treatment, but US needs new pricing and payment model
Commentary: Novartis CEO: Gene therapy offers hope of cures in one treatment, but US needs new pricing and payment model
CNBC
gene therapy
cancer
Novartis
Pharma CEOs
Vas Narasimhan
Flag link:
Actuate raises $22M to expand GSK-3β cancer trial
Actuate raises $22M to expand GSK-3β cancer trial
Fierce Biotech
Acutate Therapeutics
clinical trials
GSK-3β
cancer
Flag link:
Grail, the liquid biopsy startup, picks an approach for its cancer test
Grail, the liquid biopsy startup, picks an approach for its cancer test
Stat
Grail
diagnostics
liquid biopsy
cancer
clinical trials
Flag link:
New Eisai venture arm to focus on digital tech, dementia, cancer
New Eisai venture arm to focus on digital tech, dementia, cancer
BioCentury
Eisai
venture capital
dementia
digital technology
cancer
Flag link:
Novartis sees Saudi Arabia as promising market for producing its cancer drugs
Novartis sees Saudi Arabia as promising market for producing its cancer drugs
Fierce Pharma
Novartis
oncology
cancer
Saudi Arabia
Flag link:
Amgen, Syapse enter precision medicine collaboration in oncology
Amgen, Syapse enter precision medicine collaboration in oncology
Pharmaceutical Business Review
Amgen
Syapse
precision medicine
oncology
cancer
Flag link:

Pages